drugset / Trial / NCT01193166

Twelve Month Study Comparing Paliperidone Palmitate and Select Oral Antipsychotics in Adults With Schizophrenia Who Have Been Recently Discharged From an Inpatient Psychiatric Hospital

NCT01193166

RandomizedParallel-groupOpen-labelPrevention

Summary

The study will assess the use of paliperidone palmitate compared with oral antipsychotic treatment in delaying time to a protocol-defined treatment failure over 12 months, in patients diagnosed with schizophrenia who were recently released from an inpatient psychiatric hospital.

Timeline

Start
2010-08
Primary completion
2012-09
Completion
2012-09

Drugs

EvaluationDrugModalityDoseRoute
Comparator Aripiprazole Other / unclassified Oral
Comparator Haloperidol Other / unclassified Oral
Comparator Olanzapine Small molecule Oral
Subject Paliperidone Unknown Oral
Comparator Perphenazine Small molecule Oral
Comparator Quetiapine Small molecule Oral
Comparator Risperidone Other / unclassified Oral
Subject paliperidone palmitate Unknown 78 mg Other
Subject paliperidone palmitate Unknown 117 mg Other
Subject paliperidone palmitate Unknown 156 mg Other
Subject paliperidone palmitate Unknown 234 mg Other

Indications